An open-label, long-term safety study to evaluate the safety of the ZR-02-01 matrix transdermal fentanyl patch for the treatment of moderate to severe cancer pain
Phase of Trial: Phase III
Latest Information Update: 04 Jun 2012
At a glance
- Drugs Fentanyl (Primary)
- Indications Cancer pain
- Focus Adverse reactions; Therapeutic Use
- 04 Jun 2012 Actual patient number is 24 and additional lead trial investigator (Richard Rauck) identified as reported by ClinicalTrials.gov.
- 04 Jun 2012 Actual end date (Jul 2007) added as reported by ClinicalTrials.gov.
- 04 Jun 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.